Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia

The relationship between obsessive-compulsive disorder (OCD) and schizophrenia (SCZ) arises within an area of clinical and pathological interconnection, leading to complex diagnostic and treatment challenges. Comorbidity often leads to a poorer prognosis, including more severe symptoms, reduced social and cognitive functioning, and increased risk of suicidality.¹ The presence of obsessive-compulsive symptoms (OCS) in schizophrenia complicates management, as distinguishing between true obsessions and delusional beliefs, or between compulsions and repetitive behaviors seen in Schizophrenia, can be challenging. The term “schizo-obsessive disorder” has been proposed in the literature to describe this overlap, though large-scale validation studies are still needed, and it is not an official diagnostic designation.

The co-occurrence of OCS and SCZ has been studied for more than a century.² According to the World Health Organization, SCZ affects approximately 23 million individuals (0.29%) worldwide. The rate is slightly higher among adults (0.43%).³ OCD, on the other hand, affects about 2% to 3% of the global population (approximately 150-200 million individuals). While those with OCD do not appear any more likely than the general population to have SCZ, studies show that the prevalence of OCD symptoms in individuals with SCZ is between 20% to 30%, and the percentage of individuals with OCD ranges between 12% to 20%. Importantly, patients with SCZ have a lifetime risk of OCS that is 10 times higher than that of the average population.^1,2,4,5 It is likely that psychiatrists working in most settings will at some point encounter a patient who presents with symptoms consistent with either SCZ or OCD.

What’s In a Name?

OCD is characterized by obsessions (recurrent and persistent thoughts, urges, or images that are experienced as intrusive and unwanted) and compulsions (repetitive behaviors or mental acts done in response to an obsession.⁶ A defining feature of OCD is the significant distress caused by uncertainty regarding these thoughts. Sometimes called “the doubting disease,” OCD has the core feature of causing uncertainty about a thought (ie, “If I can’t guarantee that my hands are clean, then they are contaminated; If I can’t guarantee that I am safe, then I am definitely in danger”).

OCS, on the other hand, are obsessions and/or compulsions that may occur transiently, subclinically, or as part of another primary psychiatric disorder (see Table 1).Unlike patients with OCD, those with OCS have variable levels of distress and functional impairment. OCD thoughts are unwanted, resisted, and ego-dystonic. OCS includes thoughts that may be rationalized, and the behavior may not be resisted. For example, a 25-year-old man with schizophrenia may report repetitive touching of a stove handle before leaving the house, otherwise he “just doesn’t feel like the room will be safe.” Similarly, someone with severe depression may experience repeated intrusive images of death, which causes distress, but may not be resisted if the images are congruent with feelings of suicidality.

Underpinnings of the Schizophrenia-OCD Association

Genetic, neurobiological, and environmental studies provide insight into the overlapping symptoms between OCD and SCZ. Large-scale genome-wide association studies show that variants that increase schizophrenia risk, such as CACNA1, also independently increase risk for OCD. Genes involved in glutamatergic transmission and dopamine receptor D4, historically associated with OCD and schizophrenia, respectively, may contribute to symptom overlap. Neuroimaging studies suggest impairments in shared neuroanatomic circuits, including reduced gray matter volume, decreased left hippocampal and frontal lobe volumes, and abnormalities in frontal regions such as the dorsolateral prefrontal cortex and orbitofrontal cortex among individuals with SCZ and OCS.^2,7 Despite this evidence, it should be noted that limitations exist in terms of effect sizes and replication status for both genetic and imaging studies. Therefore, biological underpinnings remain contested, and the literature is far from convergent. Finally, environmental factors—including perinatal complications, prenatal infections, urbanicity, and trauma—also appear to increase vulnerability to both conditions.² It is unclear whether shared symptoms between OCD and SCZ stem from shared neurodevelopmental and genetic risk or represent a distinct diagnostic entity altogether.

The Role of Insight in Differentiating Disorders

The use of insight specifiers through recent versions of the DSM prompts discussion about whether a strict categorical model between OCD, OCS, and SCZ remains valid in the context of illness awareness and recognition of one’s symptoms.

DSM-IV required individuals with OCD to recognize that their obsessions or compulsions were excessive or unreasonable at some point during the illness. DSM-V-TR removed this requirement and included formal insight specifiers, allowing OCD to be diagnosed even when such recognition is absent. Insight is now categorized as “good or fair insight, poor insight, or absent insight/delusional belief,” showing a broader conceptualization of OCD that recognizes the possibility of limited or absent insight.^6,8

This shift calls into questions whether the DSM-V-TR’s insight specifier to OCD “with absent insight/delusional beliefs” blurs or clarifies the distinction between OCD and psychosis.^7,9 It also prompts questions about whether this change might lead to more cases being diagnosed as OCD that previously would have been classified on the psychosis spectrum, and, if so, the implications for diagnosis and treatment (ie, recommending a treatment plan that includes antipsychotics versus exposure therapy).^6,8

It is important to recognize that insight can also exist on a continuum and that those with poorer insight should be carefully considered before assigning a psychotic disorder diagnosis. For example, a patient with moderate to poor insight may think with certainty that they “definitely” hit a pedestrian rather than a speed bump. The patient may exaggerate the reasonableness of the thought, either to justify distress or maintain a compulsion, such as repeatedly returning to the area in search of evidence of a dead body. Such behavior may be mistaken for delusional, given the intensity of the claim and its unreasonableness despite evidence to the contrary.

Can A Spectrum-Thinking Approach Provide Clarity?

Given that the clinical picture for patients presenting with these overlapping symptoms can be obscure, one approach is to conceptualize symptoms on a schizo-obsessive “spectrum” instead of a dichotomous one. Symptoms do not always fit into neat DSM boundaries; for example, many patients with SCZ exhibit repetitive, intrusive thoughts or compulsive behaviors, while some individuals with OCD may endorse a delusional intensity of their obsessions. Neither may meet the full criteria for the other disorder. Thinking about symptoms in a more fluid, less compartmentalized way may add greater context when formulating treatment decisions. Rather than trying to identify which disorder the patient has, we can ask ourselves where the patient’s symptoms lie on the continuum. A spectrum-thinking farmwork may better represent real-world clinical complexity than firm categorical DSM diagnoses.^1,5,10

The Figure shows different categories on a proposed schizo-obsessive continuum, including OCD, OCD with absent insights/delusional beliefs (pursuant to current DSM-V-TR terminology), along with schizophrenia, OCS, and OCD. Such spectrum framework should not be treated as an established clinical tool but rather one provisional, working model for clinicians to consider.Several suggestions are listed below for clinicians to conceptualize schizo-obsessive symptoms along this spectrum:

1. Differentiate between an obsession (a thought) and a delusion (a belief). For patients with OCD, the mere presence of a thought can make a patient feel uncomfortable, and questioning the thought’s existence altogether can create great distress (ie, this doesn’t feel like me). Recognition that the thought cannot be resisted will induce even further anxiety. For diagnostic clarity, clinicians should assess how the patient arrived at the thought. For example, individuals with SCZ may experience persecutory delusions involving intentional harm by others, whereas patients with OCD are more likely to attribute feared outcomes to chance or bad luck (such as contracting a contagious illness). In contrast, delusional beliefs are generally not questioned, even when distressing. Such beliefs are ego-syntonic, integrated into the individual’s belief system, and less likely to be resisted, remaining embedded within one’s delusional framework.^1,7
2. Don’t be fooled by bizarreness. Focusing on the peculiarities of an obsession risks misidentifying it as a delusion. For instance, patients with scrupulosity-type OCD (obsessions and compulsions related to religion and mortality) will report ideas about the devil, being possessed, and sin, commonly leading to repetitive behaviors or rituals. Clinicians should look past the bizarre quality of the thought and assess the thought’s impact on everyday behavior, the plausibility if it is a belief, resistance to the thought, and associated distress.
3. Assess the fixity of the belief. Even patients with OCD who have poor insight will generally retain some doubt about the validity of their thoughts and recognize the distress it causes to struggle against them. In SCZ, beliefs are held as absolute and accepted as “real,” with little intervening doubt. Providers should assess the persistence of an idea even in the face of contrary evidence, the perceived consequences of not performing a ritual, and ask for explanations for why others do not share the belief.

A proposed category, “schizo-obsessive disorder,” has been introduced to describe individuals with SCZ and clinically significant OCS not fully explained by either condition alone. Although not recognized as a DSM diagnosis, the proposed working criteria also include obsessions or compulsions that are distinguishable from delusions, and OCS that do not exclusively occur during a psychotic episode.^11,12 Large-scale studies are still needed to validate and standardize criteria for the clinical usefulness of a formal schizo-obsessive disorder category.¹⁰

Lastly, it should be noted that adopting a spectrum-thinking approach carries potential limitations. Conceptualizing disorders on a broader scale may reduce diagnostic specificity and increase ambiguity, complicating treatment decisions, especially when presentations are complex. Despite known limitations, established categorical diagnoses still provide valuable information on prognosis and inform evidence-based treatment. Thus, one approach is to use spectrum-based frameworks applied alongside, rather than in place of, existing categorical diagnostic criteria.

Pharmacological and Treatment Considerations for Patients

Current recommended treatment strategies for patients with OCD include 4 FDA-approved selective serotonin reuptake inhibitors (fluoxetine, sertraline, fluvoxamine, and paroxetine) and 1 FDA-approved tricyclic antidepressant (clomipramine). High doses of medications are generally required to treat patients with moderate-severe OCD. Augmentation with atypical antipsychotics (AAP) can be an effective strategy to manage symptoms, especially for those with co-occurring mood or anxiety disorders (ie, the use of aripiprazole, for example). Glutamatergic agents can be used as off-label options to augment OCD treatment.⁴Although the full range and breadth of psychotherapy treatment is beyond the scope of this article, it should be noted that Exposure and response prevention (ERP)—a form of cognitive behavioral therapy—is a first-line, evidence-based treatment for obsessive-compulsive disorder (OCD). It should also be considered as an intervention for clinically significant obsessive-compulsive symptoms (OCS).

The Treatment Paradox

Given that the prevalence of OCS and OCD is higher in patients with SCZ, antipsychotics—including AAPs—are frequently used to treat patients with overlapping symptoms. However, this treatment strategy may paradoxically induce de novo OCS or aggravation of existing OCS in patients with SCZ (ie, the “treatment paradox”). Thus, treating psychosis with antipsychotics may worsen OCD symptoms. Providers should be cognizant of this risk and modify treatment plans and monitoring frequency accordingly.⁴

Second-generation antipsychotics (SGAs) differ from first-generation antipsychotics (FGAs) due to antagonism of the serotonin 5-HT2A receptor in addition to D2 dopamine blockade. This serotonergic blockade is thought to contribute to the induction and worsening of OCSs.⁴ Clozapine, which has a particularly strong 5-HT2A antagonism, carries a higher risk of inducing OCS than other SGAs.¹³ Varying intensities of D2 blockade may also be relevant, as FGAs with strong D2 receptor antagonism, such as haloperidol, are effective in OCD treatment augmentation.^4,11,14

Table 2 provides a list of commonly used antipsychotics and their potential risk of inducing OCS. In general, approximately 70% of induced OCS are due to AAPs with strong anti-serotonergic effects: clozapine, risperidone, and olanzapine, whereas haloperidol is rarely implicated.^11,14,15 Quetiapine’s lower affinity for serotonin receptors may explain its association with fewer OCS than other AAPs.^4,16 AAPs with 5-HT1A activity, such as ziprasidone and aripiprazole, generally induce fewer OCS. There are some reported cases of OCS induced or worsened by aripiprazole. ^17,18 However, it is generally thought that aripiprazole is effective at treating OCS induced by other antipsychotics, clozapine in particular.¹⁹

To mitigate the aggravating effect of OCS in patients with psychosis, a treatment protocol that is a highly individualized and arrived at through a trial-and-error process will likely yield the greatest success. As a start, clinicians may consider this general stepwise approach:

1. Stabilize psychosis using SGAs with low OCS risk (ie, aripiprazole, especially if a mood component is present).
2. Initiate high-dose SSRI for OCS. Consider clomipramine based on response to SSRI and tolerability to anticholinergic effects.
3. Monitor for paradoxical worsening of OCS with antipsychotic therapy through a baseline and follow-up YBOCS every 4 to 6 weeks.
4. Augment with glutamatergic agent if symptoms persist or are severe (memantine, NAC). Lamotrigine, riluzole, topiramate, ketamine, glycine, and ondansetron have also been shown to ease symptoms.²⁰
5. Reevaluate and modify the treatment plan if psychosis worsens or treatment intolerance is suspected.

The aforementioned treatment should be combined with psychotherapy. If OCS predominate, then exposure and response prevention therapy is recommended weekly for 13 to 20 weeks. Clinicians should closely monitor for drug–drug interactions; for example, fluvoxamine increases clozapine levels due to CYP inhibition. Given clozapine’s narrow therapeutic index, providers should closely monitor blood clozapine levels and carefully educate patients about the risk and symptoms to monitor. Finally, given that clozapine is often the most effective—yet sometimes last selected—medication for treatment-resistant schizophrenia, managing OCS in patients for whom clozapine discontinuation is not feasible presents a significant treatment challenge for the clinician. When the treatment goal is to reduce OCS while preserving its antipsychotic efficacy, a few strategies to consider include adding an SSRI, augmenting with aripiprazole or clomipramine, and including/lengthening to course of exposure and response prevention therapy.

Concluding Thoughts

The connection between OCD, OCS, and schizophrenia is complex, understudied, and carries a high illness burden. Genetic, neuroimaging, and environmental studies suggest a relationship that cannot be explained by mere coincidence. Co-occurring symptoms rarely fit rigid diagnostic boundaries, underscoring the limitations of strict models that ignore the idiosyncrasies of belief systems and behaviors that characterize these disorders. Instead, using a dimensional “spectrum” understanding that recognizes symptoms can vary along a continuum of insight, belief flexibility, and behaviors may prove useful to clinicians. Definitional disputes exist regarding characterization of these overlapping presentations and their etiologies; further research is needed to disentangle these overlapping presentations and provide tailored interventions for patients who fall along the schizo-obsessive spectrum.

Dr Dedania is an assistant professor of psychiatry and behavioral sciences at Emory University School of Medicine. She is also a forensic psychiatrist with the Emory Psychiatry & Law Service.

References

1. Cavaco TB, Ribeiro JS. Drawing the line between obsessive-compulsive disorder and schizophrenia. Cureus. 2023;15(3):e36227.

2. Pardossi S, Cuomo A, Fagiolini A. Unraveling the boundaries, overlaps, and connections between schizophrenia and obsessive-compulsive disorder. J Clin Med. 2024;13(16):4739.

3. Schizophrenia. World Health Organization. October 6, 2025. Accessed October 12, 2026. https://www.who.int/news-room/fact-sheets/detail/schizophrenia

4. Grillault-Laroche D, Gaillard A. Induced obsessive-compulsive symptoms in schizophrenia patients under atypical antipsychotics: review and hypotheses. Psychiatry Res. 2016;246:119-128.

5. Mawn L, Campbell T, Aynsworth C, et al. Comorbidity of obsessive-compulsive and psychotic experiences: a systematic review and meta-analysis. J Obsessive Compuls Relat Disord. 2020;26:100539.

6. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text rev. American Psychiatric Association Publishing; 2022.

7. Bottas A, Cooke RG, Richter MA. Comorbidity and pathophysiology of obsessive-compulsive disorder in schizophrenia: is there evidence for a schizo-obsessive subtype of schizophrenia? J Psychiatry Neurosci. 2005;30(3):187-193.

8. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association; 1994.

9. Moritz S, Leucht S, Hoyer L, et al. Towards the DSM-6: the intersection of OCD and psychosis—expert perspectives on insight in the diagnosis of OCD. Psychiatry Res. 2025;344:116306.

10. Scotti-Muzzi E, Saide OL. Schizo-obsessive spectrum disorders: an update. CNS Spectr. 2017;22(3):258-272.

11. Poyurovsky M, Zohar J, Glick I, et al. Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications. Compr Psychiatry. 2012;53(5):480-483.

12. Poyurovsky M, Weizman A, Weizman R. Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs. 2004;18(14):989-1010.

13. Reznik I, Sirota P. Obsessive-compulsive symptoms in schizophrenia: a randomized controlled trial with clozapine. J Clin Psychopharmacol. 2000;20(4):410-416

14. Schirmbeck F, Zink M. Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol. 2012;10(1):88-95.

15. Khullar A, Chue P, Tibbo P. Quetiapine and obsessive-compulsive symptoms: case report and review of atypical antipsychotic-induced obsessive-compulsive symptoms. J Psychiatry Neurosci. 2001;26(1):55-59.

16. Stahl SM. Prescriber’s Guide: Stahl’s Essential Psychopharmacology. 5th ed. Cambridge University Press; 2014.

17. Desarkar P, Das A, Nizamie SH. Aripiprazole-induced obsessive-compulsive disorder: a report of 2 cases. J Clin Psychopharmacol. 2007;27(3):305-306.

18. Mouaffak F, Gallarda T, Baylé FJ, et al. Worsening of obsessive-compulsive symptoms after treatment with aripiprazole. J Clin Psychopharmacol. 2007;27(2):237-238.

19. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69(5):720-731.

20. Marinova Z, Chuang DM, Fineberg N. Glutamate-modulating drugs as a potential therapeutic strategy in obsessive-compulsive disorder. Curr Neuropharmacol. 2017;15(7):977-995.